TXG — 10x Genomics, Inc.

—
Nasdaq · Unknown · Unknown · CIK 1770787 ·
Last close
$56.30
Market Cap
$6.77B
52W High
$102.81
52W Low
$15.18
ADV30
3,613,747
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 150,667,000 112,927,000 -16,057,000 -19,425,000 1,063,129,000 526,187,000 225,093,000
Jun 2026 151,036,000 112,497,000 -22,955,000 -17,931,000 1,030,066,000 502,512,000 204,520,000
Mar 2026 150,843,000 106,178,000 -17,046,000 -13,470,000 1,015,759,000 490,285,000 201,435,000
Dec 2025 166,030,000 113,045,000 -19,541,000 -16,252,000 1,041,365,000 473,966,000 245,039,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$127,085,000
Investing CF
$-19,652,000
Financing CF
$-2,542,000
CapEx
$-5,649,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.59
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,541,992,000
Inventory
$52,616,000
Receivables
$50,629,000
ST Investments
$49,521,000
EBIT TTM
$-16,496,000
Pretax Income TTM
$-74,890,000
Interest Exp TTM
$3,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$618,576,000
EBITDA
$-25,942,000
Free Cash Flow
$179,656,000
Enterprise Value
$7,254,282,240
Total Cash
$575,680,000
Total Debt
$75,792,000
Shares Out
120,212,296
Trailing EPS
$-0.52
Book Value
$6.41
ROE
-8.3%
ROA
-3.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 642,823,000 -110,885,000 -43,544,000 1,041,365,000 245,039,000 796,326,000 136,050,000
Dec 2024 610,785,000 -194,559,000 -182,627,000 918,636,000 208,502,000 710,134,000 6,664,000
Dec 2023 618,727,000 -204,349,000 -255,099,000 965,143,000 224,100,000 741,043,000 -15,197,000
Dec 2022 516,409,000 -167,944,000 -166,000,000 1,028,980,000 223,237,000 805,743,000 -33,606,000

TTM Snapshot

Revenues TTM
$616,911,000
NetIncome TTM
$-75,125,000
OpCashFlow TTM
—
Assets (Latest)
$1,030,066,000
Forward EPS
$0.09

Max Pain — expiry 2027-02-19

max pain strike: $65.00 · spot: $57.07 · call oi: 2,247 · put oi: 1,133
Expected Move to 2027-02-19: ±$19.50 (34.17%) — implied range $37.57 – $76.57 · ATM straddle on $55.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ESYJY easyJet plc $6.74B $9.02 —
SNHIY Sany Heavy Industries Co., Ltd./ADR $6.80B $9.44 —
LOTMY Lottomatica Group S.p.A./ADR $6.82B $29.33 —
VG Venture Global, Inc. $6.86B $12.50 —
CHDN Churchill Downs Inc $6.67B $97.28 —

News headlines (Yahoo Finance, 1h cache)

10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations
2026-11-16 21:05 · Yahoo
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
2026-11-12 17:27 · Yahoo
What Makes 10x Genomics (TXG) a Strong Position Ahead of Its H2 2026 Atera Launch?
2026-11-12 16:42 · Yahoo
TXG Q3 2026 deep dive: spatial platform launch and AI-driven demand shape outlook
2026-11-10 09:57 · Yahoo
10x Genomics (TXG) Could Be 24% Undervalued After Raising Its 2026 Revenue Outlook
2026-11-07 11:11 · Yahoo
10x Genomics Inc (TXG) (Q3 2026) Earnings Call Highlights: Atera Launch Takes Flight as Revenue ...
2026-11-06 17:13 · Yahoo
10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
2026-11-06 15:54 · Yahoo
What 10x Genomics (TXG) Said on Its Q3 Earnings Call
2026-11-06 14:14 · Yahoo
10x Genomics, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
10x Genomics (TXG) Q3 2026 Earnings Call Transcript
2026-11-06 08:31 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.